keyword
MENU ▼
Read by QxMD icon Read
search

Aclidinium

keyword
https://www.readbyqxmd.com/read/29692733/identification-of-mepenzolate-derivatives-with-long-acting-bronchodilatory-activity
#1
Ken-Ichiro Tanaka, Naoki Yamakawa, Yasunobu Yamashita, Teita Asano, Yuki Kanda, Ayaka Takafuji, Masahiro Kawahara, Mitsuko Takenaga, Yoshifumi Fukunishi, Tohru Mizushima
The standard treatment for chronic obstructive pulmonary disease is a combination of anti-inflammatory drugs and bronchodilators. We recently found that mepenzolate bromide ( MP ), an antagonist for human muscarinic M3 receptor (hM3 R), has both anti-inflammatory and short-acting bronchodilatory activities. To obtain MP derivatives with longer-lasting bronchodilatory activity, we synthesized hybrid compounds based on MP and two other muscarinic antagonists with long-acting bronchodilatory activity glycopyrronium bromide ( GC ) and aclidinium bromide ( AD )...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29670345/practical-considerations-when-prescribing-a-long-acting-muscarinic-antagonist-for-patients-with-copd
#2
REVIEW
Anthony D D'Urzo, Peter Kardos, Russell Wiseman
COPD is characterized by persistent airflow limitation, progressive breathlessness, cough, and sputum production. Long-acting muscarinic antagonists (LAMAs) are one of the recommended first-choice therapeutic options for patients with COPD, and several new agents have been developed in recent years. A literature search identified 14 published randomized, placebo-controlled studies of the efficacy and safety of LAMAs in patients with COPD, with improvements seen in lung function, exacerbations, breathlessness, and health status...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29629400/long-term-evaluation-of-the-effects-of-aclidinium-bromide-on-major-adverse-cardiovascular-events-and-copd-exacerbations-in-patients-with-moderate-to-very-severe-copd-rationale-and-design-of-the-ascent-copd-study
#3
Robert A Wise, Kenneth R Chapman, Benjamin M Scirica, David A Schoenfeld, Deepak L Bhatt, Sami Z Daoud, Beatriz Seoane, Colin Reisner, Esther Garcia Gil
Introduction: Chronic obstructive pulmonary disease (COPD) is a heterogeneous illness characterized by persistent airflow obstruction and exacerbations. Patients typically experience a decline in lung function, increasingly impaired health-related quality of life, and high mortality. Poor lung function and exacerbations are associated with an increased risk of cardiovascular (CV) and cerebrovascular events, and approximately 30% of patients with COPD die from CV‑related disease. Treatment with inhaled long-acting bronchodilators, such as long-acting muscarinic antagonists (LAMAs), is recommended; however, some studies have suggested that LAMAs may increase the risk of CV events...
January 24, 2018: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://www.readbyqxmd.com/read/29616842/the-discovery-and-development-of-aclidinium-bromide-for-the-treatment-of-chronic-obstructive-pulmonary-disease
#4
Mario Malerba, Alessandro Radaeli, Giuseppe Santini, Jaymin Morjaria, Nadia Mores, Chiara Mondino, Giuseppe Macis, Paolo Montuschi
Bronchodilators, including long-acting muscarinic receptor antagonists (LAMAs), are a mainstay of the pharmacological treatment of chronic obstructive pulmonary disease (COPD). LAMAs act as bronchodilators principally by antagonizing airway smooth muscle cells M3 muscarinic receptors. Aclidinium bromide is a twice-daily LAMA which was developed to improve on the efficacy and/or safety of previous LAMAs. Area covered: Herein, the authors present the pharmacotherapeutic role of aclidinium in COPD and point out unmet need in this research area...
April 4, 2018: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/29337266/comparison-of-the-in-vitro-pharmacological-profiles-of-long-acting-muscarinic-antagonists-in-human-bronchus
#5
Emmanuel Naline, Stanislas Grassin Delyle, Hélène Salvator, Marion Brollo, Christophe Faisy, Tatiana Victoni, Charlotte Abrial, Philippe Devillier
BACKGROUND AND PURPOSE: Long-acting muscarinic antagonists (LAMAs) have been recommended for the treatment of chronic obstructive pulmonary disease and (more recently) asthma. However, the in vitro pharmacological profiles of the four LAMAs currently marketed (tiotropium, umeclidinium, aclidinium and glycopyrronium) have not yet been compared (relative to ipratropium) by using the same experimental approach. EXPERIMENTAL APPROACH: With a total of 560 human bronchial rings, we investigated the antagonists' potency, onset and duration of action for inhibition of the contractile response evoked by electrical field stimulation...
April 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29202767/dose-selection-for-glycopyrrolate-eflow-%C3%A2-phase-iii-clinical-studies-results-from-golden-glycopyrrolate-for-obstructive-lung-disease-via-electronic-nebulizer-phase-ii-dose-finding-studies
#6
James F Donohue, Thomas Goodin, Robert Tosiello, Alistair Wheeler
BACKGROUND: Long-acting muscarinic antagonists (LAMAs) are recommended for the treatment of chronic obstructive pulmonary disease (COPD). Glycopyrrolate/eFlow® is an investigational drug-device combination of the LAMA glycopyrrolate administered by an eFlow® Closed System (eFlow® CS) nebulizer. The GOLDEN 2 (NCT01706536) and GOLDEN 6 (NCT02038829) Phase II, multicenter studies were conducted to inform dose selection for the GOLDEN Phase III clinical trials. Bronchodilator responses and safety assessments supported dose selection...
December 4, 2017: Respiratory Research
https://www.readbyqxmd.com/read/28883722/activate-the-effect-of-aclidinium-formoterol-on-hyperinflation-exercise-capacity-and-physical-activity-in-patients-with-copd
#7
Henrik Watz, Thierry Troosters, Kai M Beeh, Judith Garcia-Aymerich, Pierluigi Paggiaro, Eduard Molins, Massimo Notari, Antonio Zapata, Diana Jarreta, Esther Garcia Gil
The Phase IV, 8-week, randomized, double-blind, placebo-controlled ACTIVATE study (NCT02424344) evaluated the effect of aclidinium/formoterol (AB/FF) 400/12 μg twice daily on lung hyperinflation, exercise capacity, and physical activity in patients with moderate-to-severe COPD. Patients received AB/FF (n=134) or placebo (n=133) (1:1) via the Genuair™/Pressair® dry powder inhaler for 8 weeks. From Weeks 5 to 8, all patients participated in behavioral intervention (BI; daily messages providing step goals)...
2017: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/28767773/long-acting-muscarinic-antagonists-vs-long-acting-%C3%AE-2-agonists-in-copd-exacerbations-a-systematic-review-and-meta-analysis
#8
Israel Silva Maia, Mariângela Pimentel Pincelli, Victor Figueiredo Leite, João Amadera, Anna Maria Buehler
OBJECTIVE: To determine whether long-acting muscarinic antagonists (LAMAs) provide superior therapeutic effects over long-acting β2 agonists (LABAs) for preventing COPD exacerbations. METHODS: This was a systematic review and meta-analysis of randomized clinical trials involving patients with stable, moderate to severe COPD according to the Global Initiative for Chronic Obstructive Lung Disease criteria, treated with a LAMA (i.e., tiotropium bromide, aclidinium, or glycopyrronium), followed for at least 12 weeks and compared with controls using a LABA in isolation or in combination with a corticosteroid...
July 2017: Jornal Brasileiro de Pneumologia: Publicaça̋o Oficial da Sociedade Brasileira de Pneumologia e Tisilogia
https://www.readbyqxmd.com/read/28652725/improvement-in-24-hour-bronchodilation-and-symptom-control-with-aclidinium-bromide-versus-tiotropium-and-placebo-in-symptomatic-patients-with-copd-post-hoc-analysis-of-a-phase-iiib-study
#9
RANDOMIZED CONTROLLED TRIAL
Jutta Beier, Robert Mroz, Anne-Marie Kirsten, Ferran Chuecos, Esther Garcia Gil
BACKGROUND: A previous Phase IIIb study (NCT01462929) in patients with moderate to severe COPD demonstrated that 6 weeks of treatment with aclidinium led to improvements in 24-hour bronchodilation comparable to those with tiotropium, and improvement of symptoms versus placebo. This post hoc analysis was performed to assess the effect of treatment in the symptomatic patient group participating in the study. METHODS: Symptomatic patients (defined as those with Evaluating Respiratory Symptoms [E-RS™] in COPD baseline score ≥10 units) received aclidinium bromide 400 μg twice daily (BID), tiotropium 18 μg once daily (QD), or placebo, for 6 weeks...
2017: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/28558833/reduction-in-clinically-important-deterioration-in-chronic-obstructive-pulmonary-disease-with-aclidinium-formoterol
#10
Dave Singh, Anthony D D'Urzo, Ferran Chuecos, Anna Muñoz, Esther Garcia Gil
BACKGROUND: 'Clinically important deterioration' (CID) is a composite endpoint measuring worsening of the key clinical features of chronic obstructive pulmonary disease (COPD), namely lung function, patient-reported outcomes, and exacerbations. ACLIFORM and AUGMENT were two 24-week, randomized, double-blind, phase III studies assessing twice-daily (BID) aclidinium bromide (AB) 400 μg/formoterol fumarate (FF) 12 μg. This pooled post-hoc analysis assessed the effects of AB/FF 400/12 μg on both first and sustained CID events versus placebo and monotherapies in patients with moderate to severe COPD...
May 30, 2017: Respiratory Research
https://www.readbyqxmd.com/read/28442901/characteristics-of-copd-patients-initiating-treatment-with-aclidinium-or-tiotropium-in-primary-care-in-catalonia-a-population-based-study
#11
COMPARATIVE STUDY
Mònica Monteagudo, Montse Roset, Teresa Rodriguez-Blanco, Laura Muñoz, Marc Miravitlles
OBJECTIVE: To describe and compare demographic and clinical profile of patients newly initiated on aclidinium (ACL) or tiotropium (TIO) and identify factors associated with newly initiated ACL in real-life clinical practice during 2013 in Catalonia. DESIGN: We performed a population-based, retrospective, observational study with data obtained from the Information System for Research Development in Primary Care, a population database that contains information of 5...
2017: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/28340862/symptom-variability-and-control-in-copd-advantages-of-dual-bronchodilation-therapy
#12
REVIEW
Fabiano Di Marco, Pierachille Santus, Nicola Scichilone, Paolo Solidoro, Marco Contoli, Fulvio Braido, Angelo Guido Corsico
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder characterized by usually progressive development of airflow obstruction that is not fully reversible. While most patients will experience symptoms throughout the day or in the morning upon awakening, many patients do not experience their symptoms as constant but report variability in symptoms during the course of the day or over time. Symptom variability adversely affects patients' health status and increases the risk of COPD exacerbations...
April 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/28340861/a-randomised-double-blind-placebo-controlled-long-term-extension-study-of-the-efficacy-safety-and-tolerability-of-fixed-dose-combinations-of-aclidinium-formoterol-or-monotherapy-in-the-treatment-of-chronic-obstructive-pulmonary-disease
#13
RANDOMIZED CONTROLLED TRIAL
Anthony D'Urzo, Stephen Rennard, Edward Kerwin, James F Donohue, Alejhandra Lei, Eduard Molins, Anne Leselbaum
INTRODUCTION: Aclidinium bromide/formoterol fumarate (AB/FF) 400/12 μg efficacy and safety was demonstrated in two 6-month Phase III studies (AUGMENT and ACLIFORM) and a 12-month study in patients with moderate to severe chronic obstructive pulmonary disease (COPD). This Phase III, double-blind, placebo-controlled, 6-month AUGMENT extension investigated the long-term safety and tolerability of AB/FF 400/12 μg (NCT01572792). METHODS: Patients were randomised in AUGMENT (1:1:1:1:1) to twice-daily AB/FF 400/12 μg, AB/FF 400/6 μg, AB 400 μg, FF 12 μg or placebo...
April 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/28235977/use-of-concomitant-inhaled-corticosteroids-pooled-data-from-two-phase-iii-studies-of-aclidinium-plus-formoterol-in-copd
#14
Anthony D'Urzo, Dave Singh, Esther Garcia Gil
Bronchodilator therapy is the backbone of the management of chronic obstructive pulmonary disease. In some patients, inhaled corticosteroids can be prescribed in combination with bronchodilators. Through a subgroup analysis of pooled data from two large phase III clinical trials of bronchodilator therapy according to concomitant inhaled corticosteroid use (user vs. non-user), we sought to evaluate the clinical benefit of adding inhaled corticosteroids to dual bronchodilator therapy in chronic obstructive pulmonary disease...
February 24, 2017: NPJ Primary Care Respiratory Medicine
https://www.readbyqxmd.com/read/28228952/assessment-of-the-expectancy-seriousness-and-severity-of-adverse-drug-reactions-reported-for-chronic-obstructive-pulmonary-disease-therapy
#15
Guenka Petrova, Assena Stoimenova, Maria Dimitrova, Maria Kamusheva, Daniela Petrova, Ognian Georgiev
INTRODUCTION: Adverse drug reactions can cause increased morbidity and mortality, and therefore information needs to be studied systematically. Little is known about the adverse drug reactions for chronic obstructive pulmonary disease therapy. The goal of this study is to assess the expectedness, seriousness and severity of adverse drug reactions during chronic obstructive pulmonary disease therapy based on their reporting in the national pharmacovigilance system. METHODS: This was a prospective, observational, 1-year, real-life study about the pharmacotherapy of a sample of 390 chronic obstructive pulmonary disease patients...
2017: SAGE Open Medicine
https://www.readbyqxmd.com/read/28212954/evaluation-of-copd-treatments-a-multicriteria-decision-analysis-of-aclidinium-and-tiotropium-in-the-united-states
#16
Kevin Marsh, Erica Zaiser, Panagiotis Orfanos, Suzanne Salverda, Teresa Wilcox, Shawn Sun, Shailja Dixit
BACKGROUND: Comparisons of the use of aclidinium bromide and tiotropium bromide for the treatment of chronic obstructive pulmonary disease often concentrate on key end points (exacerbations) at the expense of other benefits and risks. Multicriteria decision analysis (MCDA) can help overcome this by using stakeholder preferences to combine multiple end points into an overall value estimate. OBJECTIVES: To evaluate the use of aclidinium bromide twice daily via Pressair™ (AstraZeneca Pharmaceuticals LP, Wilmington, DE) and of tiotropium once daily via HandiHaler® (Boehringer Ingelheim Pharmaceuticals, Inc...
January 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28187787/erratum-to-is-aclidinium-alone-or-combined-with-a-laba-a-rational-choice-for-symptomatic-copd-patients
#17
F Blasi, G W Canonica, M Miravitlles
No abstract text is available yet for this article.
February 10, 2017: Respiratory Research
https://www.readbyqxmd.com/read/28134225/-new-bronchodilation-treatment-options-for-patients-with-copd
#18
REVIEW
Tadeusz Płusa
The main aim of treatment of patients with symptoms of airway obstruction is to improve their quality of life by reducing or removing the main symptoms. To get this effect, you must be able to control the bronchial smooth muscle. This is becoming more possible by the introduction of new inhaled particles, which acting Β2-adrenergic receptors or muscarinic receptors dilate bronchial lumen. New drugs to control Β2-adrenergic receptors exhibit a long duration of action - LABA (long-acting beta-agonist), for example indacaterol, vilanterol or olodaterol can be used once a day, because their action exceeds 24 hours...
January 23, 2017: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/28115839/dual-bronchodilation-in-copd-lung-function-and-patient-reported-outcomes-a-review
#19
REVIEW
David Price, Anders Østrem, Mike Thomas, Tobias Welte
Several fixed-dose combinations (FDCs) of long-acting bronchodilators (a long-acting muscarinic antagonist [LAMA] plus a long-acting β2-agonist [LABA]) are available for the treatment of COPD. Studies of these FDCs have demonstrated substantial improvements in lung function (forced expiratory volume in 1 second) in comparison with their respective constituent monocomponents. Improvements in patient-reported outcomes (PROs), such as symptoms and health status, as well as exacerbation rates, have been reported compared with a LABA or LAMA alone, but results are less consistent...
2017: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/28100244/is-aclidinium-alone-or-combined-with-a-laba-a-rational-choice-for-symptomatic-copd-patients
#20
REVIEW
F Blasi, G W Canonica, M Miravitlles
BACKGROUND: As emphasized by international recommendations and largely confirmed by clinical experience, long-acting bronchodilators play a central role in the maintenance treatment of chronic obstructive pulmonary disease (COPD) due to their proven efficacy in reducing airflow obstruction and improving symptoms. MAIN BODY: There are some important aspects to define with regard to inhalation therapy for COPD, particularly those concerning the selection criteria and the optimal use of long-acting bronchodilators...
January 18, 2017: Respiratory Research
keyword
keyword
52233
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"